Recursion Pharmaceuticals (NASDAQ: RXRX) has been a pioneer in using artificial intelligence (AI) to improve the drug ...

The ability to respond to changing surroundings was once considered exclusive to complex living organisms. Then came ...

AI-based drug developer Recursion’s stock barely moved Wednesday, then dropped Thursday and Friday, after reporting mixed third quarter results, setting the stage for future pipeline announcements—and ...

A new physics study challenges the simulation hypothesis, arguing that the universe contains realities that can likely never ...

Welcome to this week's Chutes & Ladders, our roundup of significant leadership hirings, firings and retirings across the ...

Previous Community Perspectives have described threats posed by Artificial Intelligence (AI) and its convergence with the rapidly expanding technological ecosystem — especially nanotechnology, ...

Achieved $30 million milestone from Roche and Genentech for delivering a whole-genome map of microglial immune cells—the ...

Salt Lake City, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced today its participation in ...

It's a plot device beloved by science fiction: our entire universe might be a simulation running on some advanced ...